Search research articles
Contact Us
Filters
Showing results (31-40 of 40) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 40 results.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 13, 2017
Follow-up cancer care: perspectives of Aboriginal and Torres Strait Islander cancer survivors
J A Meiklejohn, G Garvey, R Bailie, et al.
Scandinavian Journal of Immunology
|
February 3, 2011
IgE sequences in individuals living in an area of endemic parasitism show little mutational evidence of antigen selection
Y Wang, K J L Jackson, Z Chen, et al.
Seminars in Oncology
|
November 28, 1997
A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand
J F Bishop, J Dewar, G Toner, et al.
Oncology (Williston Park, N.Y.)
|
April 1, 1997
Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand
J F Bishop, J Dewar, G C Toner, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
June 13, 2003
Relapse patterns after chemo-radiation for carcinoma of the oesophagus
J W Denham, A Steigler, J Kilmurray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer
J F Bishop, J Dewar, G C Toner, et al.
BMC Cancer
|
March 16, 2022
Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
R Mercieca-Bebber, E H Barnes, K Wilson, et al.
Breast Cancer Research and Treatment
|
November 30, 2004
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
A Di Leo, S Chan, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
G V Long, A Arance, L Mortier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
S Chan, K Friedrichs, D Noel, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 40) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 40 results.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 13, 2017
Follow-up cancer care: perspectives of Aboriginal and Torres Strait Islander cancer survivors
J A Meiklejohn, G Garvey, R Bailie, et al.
Scandinavian Journal of Immunology
|
February 3, 2011
IgE sequences in individuals living in an area of endemic parasitism show little mutational evidence of antigen selection
Y Wang, K J L Jackson, Z Chen, et al.
Seminars in Oncology
|
November 28, 1997
A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand
J F Bishop, J Dewar, G Toner, et al.
Oncology (Williston Park, N.Y.)
|
April 1, 1997
Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand
J F Bishop, J Dewar, G C Toner, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
June 13, 2003
Relapse patterns after chemo-radiation for carcinoma of the oesophagus
J W Denham, A Steigler, J Kilmurray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer
J F Bishop, J Dewar, G C Toner, et al.
BMC Cancer
|
March 16, 2022
Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
R Mercieca-Bebber, E H Barnes, K Wilson, et al.
Breast Cancer Research and Treatment
|
November 30, 2004
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
A Di Leo, S Chan, M Paesmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
G V Long, A Arance, L Mortier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
S Chan, K Friedrichs, D Noel, et al.
Page
of 4